MCF7/182R-6 Breast Cancer Cell line (resistant to fulvestrant) - tccp24487

Product Description

The MCF7/182R-6 Cell line is a breast cancer cell line resistant to fulvestrant. The MCF7/182R-6 cell line has been established from a clone of MCF7/S0.5 cells surviving long term growth with the pure steroidal antiestrogen ICI 182,780 in 100 nM concentration, see Lykkesfeldt et al (1995). The MCF7/182R-6 cells are grown in the presence of fulvestrant.

Oestrogen receptor only. Upon withdrawal of fulvestrant, the resistant phenotype is stable and the cells express ER alpha, although at a reduced level. The MCF7/182R-6 cells do not express progesterone receptor. The MCF7/182R-6 cells express increased level of EGFR, phosphorylated EGFR and phosphorylated ErbB3 and reduced level of ErbB4 compared to the parental MCF7/S0.5 cells.

The MCF7/182R-6 cell line has been established from a clone of MCF7/S0.5 cells surviving long term growth with the pure steroidal antiestrogen ICI 182,780 in 100 nM concentration, see Lykkesfeldt et al (1995). The MCF7/182R-6 cells are grown in the presence of fulvestrant.

Information

Research AreaCancer, Drug Discovery & Development

Host SpeciesHuman

TissueBreast

MorphologyPolygonal epithelial

Growth PropertiesAdherent

Specifications

FormFrozen

Misc Information

NotesUpon withdrawal of fulvestrant, the resistant phenotype is stable and the cells express ER alpha, although at a reduced level. The MCF7/182R-6 cells do not express progesterone receptor. The MCF7/182R-6 cells express increased level of EGFR, phosphorylated EGFR and phosphorylated ErbB3 and reduced level of ErbB4 compared to the parental MCF7/S0.5 cells. Passage 421 (AL2533, AL2536) In mice, estrogen supplementation is required for formation of tumours, and treatment with ICI 182, 780 inhibits tumour growth. This model is considered an in vitro model. The fulvestrant resistant cells have progressed towards reduced estrogen dependence and unpublished in vivo experiments indicate that fulvestrant resistant xenografts may be established by inoculation of MCF-7/182R-6 cells in animals treated with estrogen and then treatment with fulvestrant until regrowth of the tumor.

ProtocolPhenol red free DMEM/F12 (1:1) supplemented with 1% FCS, Glutamax 2,5 mM and 6 ng/ml insulin. Supplemented with 100nM fulvestrant to maintain resistance.
Subculture Routine:Split sub-confluent cultures (70-80%) 1:3 to 1:6 i.e. seeding at 2-4x104 cells/cm² using 0.05% trypsin or trypsin or trypsin/EDTA; 5% CO2; 37°C

tccp24487 MCF7/182R-6 Breast Cancer Cell line (resistant to fulvestrant)

Data sheet

Download PDF Datasheet

Technical Inquries

Submit Review

Submit Review

Product Description

Information

Specifications

Misc Information